Hippocampal grafts derived from embryonic trisomy 16 mice exhibit amyloid (A4) and neurofibrillary pathology.
Explore the source record for details and available documents.
Alzheimer Disease↗
Biomedical subjects
C L Masters
Publications and source records attributed to C L Masters.
Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.
In the brains of aged humans and cases of Alzheimer disease, deposits of amyloid in senile plaques are located in proximity to nerve processes. The principal component of this extracellular amyloid is beta/A4, a peptide derived from a larger amyloid precursor protein (APP), which is actively expressed in brain and systemic organs. Mechanisms that result in the proteolysis of APP to form beta/A4, previously termed beta-amyloid protein, and the subsequent deposition of the peptide in brain are unknown. If beta/A4 in senile plaques is derived from neuronally synthesized APP and deposited at locations remote from sites of synthesis, then APP must be transported from neuronal cell bodies to distal nerve processes in proximity to deposits of amyloid. In this study, using several immunodetection methods, we demonstrate that APP is transported axonally in neurons of the rat peripheral nervous system. Moreover, our investigations show that APP is transported by means of the fast anterograde component. These findings are consistent with the hypothesis of a neuronal origin of beta/A4, in which amyloid is deposited in the brain parenchyma of aged individuals and cases of Alzheimer disease. In this setting, we suggest that APP is synthesized in neurons and delivered to dystrophic nerve endings, where subsequent alterations of local processing of APP result in deposits of brain amyloid.
Acetylcholinesterase↗
Entry of neurotropic arboviruses into the central nervous system: an in vitro study using mouse brain endothelium.
Arbovirus infection of cerebral microvascular endothelial cells was investigated in an in vitro mouse brain endothelial (MBE) cell model. Alphaviruses replicated to a greater extent than did flaviviruses, indicating that viremia may be important in neuroinvasion. Also, some viruses (e.g., Semliki Forest virus) replicated to high titers while others (e.g., Murray Valley encephalitis virus) did not. Viruses that replicated to high titers showed luminal polarity of virus release, indicating that infection of the endothelium may be important in both maintenance of viremia and neuroinvasion; viruses that did not so replicate showed abluminal polarity of release, indicating that virus is actively transported across the endothelial monolayer, another mechanism for neuroinvasion. Infection of MBE cells with highly and less-neuroinvasive strains achieved similar results, indicating that the endothelium does not discriminate between neuroinvasive strains. However, the cerebral microvascular endothelium may be important in discriminating between viruses that invade the brain parenchyma and those that do not: neuron-tropic Ross River virus T48 replicated to higher titers than did ependymal-tropic Ross River virus NB5092. Thus, viruses probably use multiple cellular mechanisms to invade the central nervous system across the cerebral microvascular endothelium.
Alphavirus↗
Creutzfeldt-Jakob disease and slow infections: a review.
Explore the source record for details and available documents.
Creutzfeldt-Jakob Syndrome↗
Protein abnormalities in neurofibrillary tangles: their relation to the extracellular amyloid deposits of the A4 protein in Alzheimer's disease.
Explore the source record for details and available documents.
Alzheimer Disease↗
Identification of a beta-turn in the tertiary structure of a peptide fragment of the Alzheimer amyloid protein.
In an attempt to understand the three-dimensional structure of the Alzheimer amyloid protein, a fragment decapeptide was studied by nuclear magnetic resonance spectroscopy. Using two-dimensional techniques, protons close in space were identified and their interproton distances determined. These distances were then used as input data for distance geometry calculations. The resulting three-dimensional structures suggest the presence of a beta-turn in the C-terminus of the decapeptide.
Amino Acid Sequence↗
Ultrastructural localization of the putative precursors of the A4 amyloid protein associated with Alzheimer's disease.
Any explanation of the causes of Alzheimer's disease and of its unique cerebral pathologic features must take into account the distribution and ultrastructural localization of the pre-A4 amyloid proteins in tissues and organs. The authors have analyzed the expression of the pre-A4 amyloid proteins in several tissues by immunogold electron microscopy and by immunofluorescence. For this purpose, they have used a mouse monoclonal antibody and a guinea pig antiserum raised against two synthetic peptides corresponding to two different sequences common to all the full-length forms of the A4 amyloid precursors. They observed a tissue-specific distribution of the secreted and the transmembrane form of the precursors. The authors could determine that the secreted form is generated in vivo within the cytoplasm. In the salivary glands and in the adenohypophysis, all the immunoreactivity is associated with the process of secretion, whereas in the muscle, a staining pattern compatible with the presence of the pre-A4 amyloid proteins in the sarcoplasmic reticulum has been observed. This difference in the localization may reflect tissue-specific processing pathways and suggests that posttranslational modifications such as proteolytic removal of the transmembrane and cytoplasmic domains contribute to the structural and thus functional diversity of the A4 amyloid precursors.
Alzheimer Disease↗
A4 amyloid protein immunoreactivity is present in Alzheimer's disease neurofibrillary tangles.
Neurofibrillary tangles and neuritic plaques are the neuropathological hallmarks of Alzheimer's disease. The latter consist of a core of A4 amyloid protein. We now report that some neurofibrillary tangles ('tombstone tangles') are also A4 immunoreactive. This observation is consistent with the hypothesis that A4 amyloid accumulation is a component of both neurofibrillary tangles and neuritic plaques.
Alzheimer Disease↗
Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.
In patients with Alzheimer's disease, amyloid fibrils that are aggregates of A4 protein subunits are deposited in the brain. A similar process occurs at an earlier age in persons with Down's syndrome. To investigate the deposition of amyloid in these diseases, we used a radioimmunoassay to measure levels of the amyloid precursor (PreA4) in the serum of 17 patients with Down's syndrome, 15 patients with Alzheimer's disease, and 33 normal elderly controls. The mean (+/- SD) concentration of serum PreA4 was increased 1.5-fold in patients with Down's syndrome (2.49 +/- 1.13 nmol per liter) as compared with that in controls (1.68 +/- 0.49 nmol per liter; P less than 0.007); the levels in patients with Alzheimer's disease were similar to those in controls (1.83 +/- 0.78; P less than 0.98). We also found that the concentration of PreA4 in the brain tissue of two adults with Down's syndrome (100 and 190 pmol per gram) was higher than that in the brain tissue of either 26 patients with Alzheimer's disease (64.4 +/- 17.3 pmol per gram) or 17 elderly controls with neurologic disease (68.5 +/- 26.3 pmol per gram). Immunocytochemical studies of brain tissue from 26 patients with Down's syndrome showed that the deposition of A4 protein amyloid began in these patients approximately 50 years earlier than it began in 127 normal aging subjects studied previously, although the rate of deposition was the same. We conclude that, since the gene for PreA4 is on the long arm of chromosome 21, which is present in triplicate in Down's syndrome, overexpression of this gene may lead to increased levels of PreA4 and amyloid deposition in Down's syndrome. However, since increased levels of PreA4 are not present in Alzheimer's disease, additional factors must account for the amyloid deposition in that disorder.
Adolescent↗
Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein.
To study the putative precursor proteins (PreA4(695), PreA4(751), and PreA4(770] of Alzheimer's disease A4 amyloid protein, polyclonal and monoclonal antibodies were raised against a recombinant bacterial PreA4(695) fusion protein. These antibodies were used to identify the precursors in different cell lines as well as in human brain homogenates and cerebrospinal fluid (CSF). The precursors are tyrosine-sulfated, O- and N-glycosylated membrane proteins and have half-lives of 20-30 min in cells. Cells express the polypeptides at their surface but also secrete C-terminal truncated proteins into the medium. These proteins are also found in CSF of both Alzheimer's disease patients and normal individuals. The proteins are derived from their cognate membrane-associated forms by proteolysis and have apparently lost the cytoplasmic and the transmembrane domains. Since the latter contributes to the A4 amyloid sequence, it seems possible that this proteolytic cleavage represents the first step in the formation of A4 amyloid deposits.
Alzheimer Disease↗
A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition.
This study was designed to investigate the role of serum proteins, microglia, glial fibrillary acidic protein (GFAP) positive cells and dystrophic neurites in the genesis of cerebral amyloid. Using A4 protein antisera, we found an amorphous non-congophilic, form of plaque, which was not seen in Bielschowsky silver staining or Bodian impregnations. GFAP-positive glial cells, cells immunolabelled for some macrophage markers and dystrophic neurites were detected in congophilic plaques with crystalline amyloid, but not in the amorphous, non-congophilic plaques. The presence of alpha l-antichymotrypsin, complement factors and P component, but not of common serum proteins in both the amorphous and congophilic plaques, indicates that these three proteins may have a pathogenetic role in amyloid formation. Amorphous plaques may be the earlier forms of plaque and consequently, the presence of reactive cells and dystrophic neurites may be secondary phenomena.
Alzheimer Disease↗
Gerstmann-Sträussler-Scheinker disease. II. Neurofibrillary tangles and plaques with PrP-amyloid coexist in an affected family.
Azzarelli et al reported an Indiana kindred affected by a hereditary disorder, characterized clinically by ataxia, parkinsonism, and dementia. Recently, we studied neuropathologically the 3rd and 4th cases that came to autopsy among the patients of this family. As in 2 patients examined previously, amyloid plaques were widespread throughout the cerebrum and the cerebellum, whereas neurofibrillary tangles were numerous in the cerebral cortex, the hippocampus, and the substantia innominata. Amyloid plaques were not recognized by polyclonal antibodies against the Alzheimer's disease amyloid A4 protein, but did contain epitopes recognized by antibodies against a prion protein. Spongiform changes were occasionally observed and were mild. Our findings indicate that this familial disorder is a form of or is related to Gerstmann-Sträussler-Scheinker disease. The consistent presence of numerous neurofibrillary tangles may be important in differentiating a distinct subgroup of patients with familial Gerstmann-Sträussler-Scheinker disease, and indicates that a disturbance of the cytoskeleton might be part of the neuronal pathology of Gerstmann-Sträussler-Scheinker disease.
Amyloid↗
Familial dementia with PrP-positive amyloid plaques: a variant of Gerstmann-Sträussler syndrome.
We present a 22-year follow-up of a large and unusual kindred previously reported as familial Alzheimer's disease (FAD). However, detailed clinical and neuropathologic evaluation of family members and brain autopsy on another affected individual now make the diagnosis of FAD unlikely. Our patient, as well as members of this family, had numerous amyloid plaques and rare neurofibrillary tangles. These plaques were quite atypical for Alzheimer's disease (AD); many were quite large (up to 500 microns in diameter) and contained several amyloid cores, some with neuritic components. The plaques were present throughout the cerebral cortex and striatum, but not in the cerebellum. By electron microscopy, they had radiating star-shaped amyloid cores containing 8- to 10-nm fibrils, and a few dystrophic neurites. They were strongly immunoreactive with antiserum to prion protein but did not react with the antiserum to the amyloid A4 protein of AD. Although the cerebellum was uninvolved, this family appears to represent another clinical and neuropathologic variant of Gerstmann-Sträussler syndrome.
Adult↗
The pathology of the amyloid A4 precursor of Alzheimer's disease.
The A4 amyloid protein is the major subunit present in the amyloid of Alzheimer's disease. It is derived by proteolytic cleavage from a larger precursor (PreA4) which is a neuronal membrane glycoprotein. Whereas in Down's syndrome, over-expression of the gene coding for PreA4 is likely to be responsible for the premature development of cerebral amyloidosis, a similar mechanism is yet to be demonstrated in Alzheimer's disease.
Alzheimer Disease↗
PreA4 mRNA distribution in brain areas.
The A4 amyloid precursor gene of Alzheimer's Disease (PreA4 gene, App gene, PAD gene) gives rise to three different transcripts, which are generated by alternative splicing. The three transcripts are PreA4695, PreA4751 and PreA4770, according to the number of amino-acids in the primary translation product. Previous expression studies did not discriminate between PreA4751 and PreA4770. We have analyzed the distribution of PreA4 transcripts in four cortical brain areas in a way that allows us the selective identification of each transcript. We used a sensitive S1 nuclease protection assay with a probe derived from PreA4770 cDNA. This radiolabeled probe gives rise to three specifically protected DNA fragments, each corresponding to one of the three PreA4 transcripts. These fragments could readily be resolved in a single lane of a denaturing polyacrylamide gel. PreA4 transcripts were quantified by scanning autoradiograms. In younger individuals PreA4695 mRNA is the dominant transcript with 55% (mean values). PreA4770 mRNA is the minor PreA4 transcript with less than 5% and PreA4751 ranges at 40%. The exception is observed in occipital cortex, where PreA4751 (50%) is higher than PreA695 (45%). A different situation was observed in older individuals. In the latter PreA4(695) transcripts are significantly reduced, with the exception of frontal cortex, whereas PreA4770 transcripts show an increase. PreA4751 has a constant level of 45% and becomes the dominant transcript.
Age Factors↗
Molecular pathology of the amyloid A4 precursor of Alzheimer's disease.
The precursor of the Alzheimer's disease-specific amyloid A4 protein is an integral, glycosylated membrane protein which spans the bilayer once. The carboxy-terminal domain of 47 residues was located at the cytoplasmic site of the membrane. The three domains following the transient signal sequence of 17 residues face the opposite side of the membrane. The C-terminal 100 residues of the precursor comprising the amyloid A4 part and the cytoplasmic domain have a high tendency to aggregate. This finding suggests that there is a precursor-product relationship between precursor and amyloid A4. We suggest that besides proteolytic cleavage, other events, such as membrane damage are primary events that precede the release of the small, aggregating amyloid A4 subunit.
Alzheimer Disease↗
The promoter of Alzheimer's disease amyloid A4 precursor gene.
The promoter of the gene for the precursor of Alzheimer's Disease A4 amyloid protein (PAD gene) resembles promoters of housekeeping genes. A typical TATA box is missing, and transcription initiates at multiple sites. It shows a high GC content of 72% in a DNA region that confers promoter activity to a reporter gene in vivo. Upstream of the RNA start sites we found sequences homologous to the consensus binding sites of transcription factor AP-1 and the heat shock control element binding protein. Six copies of a 9bp long GC-rich element are located between positions -100 and -200 of the sequence. A protein-DNA interaction could be mapped to this element. The ratio of the dinucleotide CpG, the target for DNA methylation, versus GpC is about 1:1 around the RNA start site, in contrast to the normal ratio of 1:5 in eucaryotic DNA. These findings suggest that four mechanisms may participate in the regulation of the PAD gene: the stress-related heat shock; the AP-1/Fos binding; the GC-rich element, and the possible methylation of the CpG region. PAD gene regulation could be of relevance for the progression of amyloid deposition in Alzheimer's Disease.
Alzheimer Disease↗
Deposition of Alzheimer's disease amyloid (A4) protein in the cerebral cortex in Parkinson's disease.
The prevalence of deposition of the Alzheimer's disease A4 amyloid protein in representative areas of the cerebral cortex was compared using a sensitive immunohistochemical technique in a group of 26 cases of idiopathic Parkinson's disease (PD) and in a control group of 82 subjects of comparable age who had died unexpectedly from non-cerebral causes. Cortical A4 protein deposition was found in 54% of PD subjects and 48% of the control group, while deposition of A4 protein in meningeal or cortical blood vessels was found in 38% of PD subjects and 25% of controls. When allowance was made for age and sex, the differences between the two groups were not found to be statistically significant. Heavy cortical A4 protein deposition was found in a number of PD cases, including two of four cases with dementia, and was absent in the other two cases. The present findings indicate that a large proportion of cases of idiopathic PD have associated Alzheimer's disease changes. In some cases these lesions are of sufficient severity to account for dementia. In other cases the changes are less severe and are probably subclinical but may be a contributory factor to the development of cognitive impairment and dementia. The absence of Alzheimer changes in some demented PD cases indicates that the dementia of PD is heterogeneous.
Aged↗